

Special Issue

PET/CT in Multiple Myeloma Patients

Message from the Guest Editors

Over the past decades, positron emission tomography/computed tomography (PET/CT) with ^{18}F -fluorodeoxyglucose (^{18}F -FDG) has increasingly been used in the management of multiple myeloma and other clonal proliferative plasma cell disorders as it provides useful information on patient prognosis and is the tool of choice in treatment response assessment. In addition, new PET/CT tracers targeting different metabolic pathways (such as ^{11}C -methionine, ^{11}C -/ ^{18}F -choline) or receptors expressed by multiple myeloma cells (such as C-X-C motif chemokine receptor 4) and acting as molecular imaging biomarkers have been introduced and might provide advantages over the standard ^{18}F -FDG. This special issue aims to provide a comprehensive overview over the use of ^{18}F -FDG PET/CT and new tracers in patients with multiple myeloma and other plasma cell disorders, such as smouldering multiple myeloma and solitary plasmacytoma. In addition, an outlook to new analytic (radiomics), theranostic approaches (including immuno-PET) and functional MRI (including PET/MRI) will be given.

Guest Editors

Dr. Caroline Bodet-Milin

Dr. Cristina Nanni

Dr. Constantin Lapa

Deadline for manuscript submissions

closed (31 July 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/30334

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)